Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
CIN 2/3
Interventions
DRUG

Artesunate

Patients with HPV positive CIN2/3 will receive 3 cycles of oral artesunate 200mg OD prior to standard of care therapeutic LLETZ. Each 21 day treatment cycle will comprise oral artesunate 200mg OD for 14 days followed by a 7 day treatment break.

Trial Locations (5)

59100

Pusat Perubatan Universiti Malaya, Kuala Lumpur

62250

Institut Kanser Negara, Putrajaya

68000

Hospital Ampang, Ampang

68100

Hospital Selayang, Batu Caves

93586

Hospital Umum Sarawak, Kuching

Sponsors
All Listed Sponsors
collaborator

Clinical Research Malaysia

UNKNOWN

lead

Metanoic Health Ltd.

INDUSTRY